Exclusive Summary

• • Off-patent dual-action antihistamine (H1 + PAF) with broad global use, enabling rapid multi-country distribution launches.
• • Addresses two high-burden indications—allergic rhinitis (≥400M patients) and chronic spontaneous urticaria (tens of millions)—with convenient once-daily 10 mg dosing.
• • Aligned with ARIA and EAACI/WAO guidelines that place second-generation antihistamines as first-line, despite not being on the WHO EML.
• • China VBP participation signals stable large-scale supply and low cost base, supporting 50–70% discounts vs originator/legacy brands in many markets.
• • Competition is multi-source but uneven across regions; dual-mechanism positioning helps differentiate versus older antihistamines in under-penetrated tender and private channels.